Results 31 to 40 of about 917,566 (209)

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis

open access: yesHaematologica, 2018
Systemic mastocytosis is a complex disease defined by abnormal growth and accumulation of neoplastic mast cells in various organs. Most patients exhibit a D816V-mutated variant of KIT, which confers resistance against imatinib.
Mathias Schneeweiss   +19 more
doaj   +1 more source

Mast Cell Sarcoma of the Retroperitoneum With Concurrent Systemic Mastocytosis and an Undisclosed Associated Hematologic Neoplasm: A Case Report

open access: yesClinical Pathology, 2022
Mastocytosis is a rare disorder affecting both children and adults by gathering of functionally defective mast cells in the body’s tissues. The World Health Organization (WHO) classified mastocytosis into cutaneous mastocytosis, systemic mastocytosis (SM)
Ing Chen   +4 more
doaj   +1 more source

[Systemic mastocytosis].

open access: yesMedicina cutanea ibero-latino-americana, 1989
213
Almagro Sanchez, M.   +4 more
openaire   +4 more sources

Solitary mastocytoma presenting in an adult: report and literature review of adult-onset solitary cutaneous mastocytoma with recommendations for evaluation and treatment

open access: yesDermatology Practical & Conceptual, 2016
Background: Mastocytosis is either cutaneous (with skin-limited proliferation of mast cells) or systemic (with mast cells in extracutaneous sites). The onset of solitary mastocytoma in an adult is rare.
Philip R. Cohen
doaj   +1 more source

Review and Updates on Systemic Mastocytosis and Related Entities

open access: yes, 2023
Mast cell disorders range from benign proliferations to systemic diseases that cause anaphylaxis and other diverse symptoms to mast cell neoplasms with varied clinical outcomes.
Lynn C. Moscinski   +7 more
core   +1 more source

An intriguing coexistence of cutaneous and systemic mastocytosis with atypical chronic myeloid leukemia: An associated hematologic neoplasm (SM-AHN)

open access: yesJournal of Applied Hematology, 2021
Systemic mastocytosis (SM) characterized by focal or diffuse infiltrates of neoplastic mast cells can range from indolent cutaneous disease to aggressive systemic disease.
B R Rajalakshmi, Vijaya Basavaraj
doaj   +1 more source

Coexistence of immunophenotypically normal and aberrant mast cells in patients with clonal mast cell diseases associates with more indolent subtypes and less severe disease characteristics

open access: yesCytometry Part B: Clinical Cytometry, EarlyView.
Abstract Aberrant antigen expression on mast cells (MCs) is one of the most accurate diagnostic markers for clonal MC diseases (CMCD). Although the coexistence of normal and pathologic MCs is frequently seen, the disease characteristics associated with it have been minimally investigated.
Abdulrazzaq Alheraky   +6 more
wiley   +1 more source

Apigenin Protects Hypertensive Intracerebral Hemorrhage by Regulating Trx1 Through Binding to PRDX2

open access: yesPhytotherapy Research, EarlyView.
ABSTRACT Intracerebral hemorrhage (ICH) remains the most severe stroke subtype with high mortality and disability rates. Although apigenin has shown cerebroprotective potential in preclinical studies, its mechanism of action, particularly in hypertensive ICH, remains poorly understood.
Hao‐chen Xu   +6 more
wiley   +1 more source

Gastrointestinal tract involvement in systemic mastocytosis: a clinical case

open access: yesPatologìâ
Mastocytosis is a group of rare heterogeneous diseases caused by excessive proliferation and accumulation of mast cells in various organs and systems.
Ya. S. Bereznytskyi   +5 more
doaj   +1 more source

Cutaneous and Gastrointestinal Symptoms in Two Patients with Systemic Mastocytosis Successfully Treated with Omalizumab

open access: yesCase Reports in Medicine, 2015
The pathogenesis of mastocytosis is not well defined and thus treatment remains challenging and remains on a palliative basis. We present two cases (a 48-year-old woman and a 57-year-old man) with indolent systemic mastocytosis in whom omalizumab (anti ...
Sofie Lieberoth, Simon Francis Thomsen
doaj   +1 more source

Home - About - Disclaimer - Privacy